mdlinx mdlinx
Rheumatology Articles on MDLinx
Latest (20) Full Text Top Read since last login Focus on Rheumatologic Skin Disorders Article Summary

Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes Full Text
Arthritis Research & Therapy, 08/22/2011

Yan D et al. – FGFR1 is the major mediator with the degenerative potential in the presence of FGF-2 in human adult articular chondrocytes. FGFR1 activation by FGF-2 promotes catabolism and impedes anabolism. Disruption of the balance between FGFR1 and FGFR3 signaling ratio may contribute to the pathophysiology of OA.

Methods

  • Primary human articular chondrocytes were cultured in monolayer (24 hours) or alginate beads (21 days), and stimulated with FGF-2 or FGF18, in the presence or absence of FGFR1 (FGF receptor 1) inhibitor
  • Proteoglycan accumulation and chondrocyte proliferation were assessed by dimethylmethylene blue (DMMB) assay and DNA assay, respectively
  • Expression of FGFRs (FGFR1~FGFR4) was assessed by flow cytometry, immunoblotting, and quantitative real-time PCR (qPCR)
  • Distinctive roles of FGFR1 and FGFR3 after stimulation with FGF-2 were evaluated using either pharmacological inhibitors or FGFR small interfering RNA (siRNA)

Results
  • Chondrocyte proliferation was significantly enhanced in the presence of FGF-2 stimulation, which was inhibited by the pharmacological inhibitor of FGFR1
  • Proteoglycan accumulation reduced by 50% in presence of FGF-2, and this reduction was successfully rescued by FGFR1 inhibitor
  • FGFR1 inhibitors also fully reversed the upregulation of MMP-13 expression and promoter activity stimulated by FGF-2
  • Blockade of FGFR1 signaling by either chemical inhibitors or siRNA targeting FGFR1 rather than FGFR3 abrogated the upregulation of matrix metalloproteinases 13 (MMP-13) and a disintegrin and metalloproteinase with a thrombospondin type 1 motif 5 (ADAMTS5), as well as downregulation of aggrecan after FGF-2 stimulation
  • Flow cytometry, qPCR and immunoblotting analyses suggested that FGFR1 and FGFR3 were the major FGFR isoforms expressed in human articular chondrocytes
  • FGFR1 was activated more potently than FGFR3 upon FGF-2 stimulation
  • In osteoarthritic chondrocytes, FGFR3 was significantly down regulated (P<0.05) with a concomitant increase in FGFR1 to FGFR3 expression ratio (P<0.05), compared to normal chondrocytes
  • Results demonstrate that FGFR3 was negatively regulated by FGF-2 at transcriptional level through FGFR1-ERK (extracellular signal-regulated kinase) signaling pathway in human articular chondrocytes

Read this article in Arthritis Research & Therapy read MDLinx article: Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes

<< Previous Article | Next Article >>
Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Most Popular Rheumatology Articles

Last month's top read Top 50 of 2011

1 Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis Modern Rheumatology, May 9, 2012    Clinical Article

2 Impact of statin discontinuation on mortality in patients with rheumatoid arthritis - A population-based study Arthritis Care and Research , May 1, 2012    Clinical Article

3 Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials Annals of Rheumatic Diseases, May 23, 2012    Clinical Article

4 Association between systemic anti-psoriatic drugs and cardiovascular risk in patients with psoriasis and psoriatic arthritis: A nationwide cohort study Arthritis & Rheumatism, May 4, 2012    Clinical Article

5 Effectiveness of Nigella sativa Oil in the Management of Rheumatoid Arthritis Patients: A Placebo Controlled Study Phytotherapy Research, May 7, 2012    Clinical Article

6 Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol Arthritis & Rheumatism, April 16, 2012    Clinical Article

7 Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis. Results of a 12 month open-label randomized study. Full Text Arthritis Research & Therapy, May 18, 2012    Free full text    Clinical Article

8 Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials Annals of Rheumatic Diseases, May 10, 2012    Clinical Article

9 Rilonacept (Interleukin-1 Trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results of the presurge-1 trial Arthritis Care and Research , May 7, 2012    Clinical Article

10 A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early, aggressive rheumatoid arthritis Arthritis & Rheumatism, April 30, 2012    Clinical Article

11 Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2) Annals of Rheumatic Diseases, May 10, 2012    Clinical Article

12 Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial Rheumatology, May 21, 2012    Clinical Article

13 Intra-Articular Glucocorticosteroid Injection into Sternocostoclavicular Joints in Patients with SAPHO Syndrome Seminars in Arthritis and Rheumatism, May 8, 2012    Clinical Article

14 Vitamin D and Bone Current Osteoporosis Reports, May 9, 2012    Clinical Article

15 A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone Arthritis & Rheumatism, April 24, 2012    Clinical Article

16 Mizoribine, tacrolimus, and corticosteroid combination therapy successfully induces remission in patients with lupus nephritis Clinical and Experimental Nephrology, April 17, 2012    Clinical Article

17 A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai Biologics Communication Registry (TBCR) Study Modern Rheumatology, May 3, 2012    Clinical Article

18 Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study Arthritis & Rheumatism, April 30, 2012    Clinical Article

19 Evidence-Based Knee Injections for the Management of Arthritis Pain Medicine, May 25, 2012    Evidence Based Medicine    Clinical Article

20 Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohns disease Annals of Rheumatic Diseases, May 24, 2012    Clinical Article

Indexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatologymore

Other Topics in Rheumatology

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Edit My Newsletter Settings

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close